Home » Stocks » ALXN

Alexion Pharmaceuticals, Inc. (ALXN)

Stock Price: $120.94 USD -0.12 (-0.10%)
Updated December 4, 9:52 AM EST - Market open

ALXN Stock Price Chart

Key Info

Market Cap 26.47B
Revenue (ttm) 5.86B
Net Income (ttm) 956.60M
Shares Out 219.10M
EPS (ttm) 4.31
PE Ratio 28.07
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $120.94
Previous Close $121.06
Change ($) -0.12
Change (%) -0.10%
Day's Open 121.23
Day's Range 120.30 - 121.44
Day's Volume 91,646
52-Week Range 75.56 - 127.81

ALXN Stock News

GuruFocus - 20 hours ago

Polaris Capital Management leader Bernard Horn (Trades, Portfolio) released his third-quarter portfolio earlier this week.

Other stocks mentioned: INGR, INTC, SAIC, TPR
The Motley Fool - 3 days ago

These two biotech companies are safe bargains in today's volatile market.

Other stocks mentioned: ITCI
The Motley Fool - 5 days ago

These value stocks could be the prime beneficiaries of a young but thriving bull market.

Other stocks mentioned: CVS, KL, WDC, WFC
24/7 Wall Street - 1 week ago

The short interest data are out for November 13, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big p...

Other stocks mentioned: AMGN, BIIB, GILD, MRNA, REGN, VRTX
Zacks Investment Research - 1 week ago

Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.

Business Wire - 2 weeks ago

BOSTON--(BUSINESS WIRE)--Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time

The Motley Fool - 2 weeks ago

Value investors, get those shopping carts ready.

Other stocks mentioned: MO, WBA, WDC
The Motley Fool - 2 weeks ago

These stocks can bring investors substantial returns for many years to come.

Other stocks mentioned: MA, NFLX
The Motley Fool - 2 weeks ago

These companies are devoted to helping patients who don't have any other options.

Other stocks mentioned: ORTX
Zacks Investment Research - 2 weeks ago

Let's see if Alexion Pharmaceuticals, Inc. (ALXN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top p...

The Motley Fool - 2 weeks ago

Owning innovative companies with clear-cut competitive advantages is a recipe for wealth creation.

Other stocks mentioned: FSLY, GTBIF, ISRG, MA, NEE, PINS, SIRI, SQ
Investors Business Daily - 3 weeks ago

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable appeared fi...

Other stocks mentioned: AMGN, BAYRY, REGN, SNY
Business Wire - 3 weeks ago

BOSTON--(BUSINESS WIRE)--Alexion to Present at Upcoming Virtual Investor Conferences

Investors Business Daily - 4 weeks ago

Alexion Pharmaceuticals sees its Relative Strength Rating enter the 80-plus level. The post Stock Upgrades: Alexion Pharmaceuticals Shows Rising Relative Strength appeared first on Investor's ...

Business Wire - 4 weeks ago

BOSTON--(BUSINESS WIRE)--Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

The Motley Fool - 1 month ago

A falling market represents the perfect opportunity to buy into these game-changing companies.

Other stocks mentioned: AVGO, OKTA
The Motley Fool - 1 month ago

The biotech delivered strong top- and bottom-line growth and boosted its full-year outlook.

Seeking Alpha - 1 month ago

Alexion Pharmaceuticals' (ALXN) CEO Ludwig Hantson on Q3 2020 Results - Earnings Call Transcript

GuruFocus - 1 month ago

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) sold shares of the following stocks during its third quarter of fiscal 2020, which ended on Sept. 30.

Other stocks mentioned: GILD
Zacks Investment Research - 1 month ago

Alexion (ALXN) beats earnings and sales estimates in the third quarter of 2020.

Zacks Investment Research - 1 month ago

Alexion (ALXN) delivered earnings and revenue surprises of 25.10% and 11.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 1 month ago

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) moved higher by 6.7% in pre-market trading after the company reported Q3 results.

Investors Business Daily - 1 month ago

Alexion Pharmaceuticals earnings and revenue easily beat Q3 views. The biotech giant also raised full-year guidance, after saying it would.

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Alexion Reports Third Quarter 2020 Results

GuruFocus - 1 month ago

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the third quarter of the year earlier this week.

Other stocks mentioned: ABBV, BMRN, BMY, GILD
Zacks Investment Research - 1 month ago

Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Motley Fool - 1 month ago

These two rare-disease drug developers are experts at penetrating their markets.

Other stocks mentioned: VRTX
24/7 Wall Street - 1 month ago

The short interest data are out for October 15, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big po...

Other stocks mentioned: AMGN, BIIB, GILD, MRNA, REGN, VRTX
The Motley Fool - 1 month ago

These two companies are well-positioned to deliver market-beating returns for years to come.

Other stocks mentioned: BMY
Zacks Investment Research - 1 month ago

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 month ago

Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Alexion to Report Third Quarter 2020 Results on Thursday, October 29, 2020

GuruFocus - 1 month ago

The health care strategy analyst at Jefferies said he expects to see acquisitions in the pharma and biotech space in the $5 billion to $10 billion range, according to an article in FierceBiote...

Other stocks mentioned: AMRN, BMRN
24/7 Wall Street - 1 month ago

Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.

Other stocks mentioned: AMGN, BMRN, INSM, REGN, UTHR, VRTX
The Motley Fool - 1 month ago

With a strong grip on its target markets and a promising pipeline, this company should continue to grow.

Zacks Investment Research - 1 month ago

Alexion (ALXN) gets FDA approval for Ultomiris 100 mg/mL, a new advanced formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

24/7 Wall Street - 1 month ago

The short interest data are out for September 30, the most recent settlement date.

Other stocks mentioned: AMGN, BIIB, GILD, MRNA, REGN, VRTX
Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Alexion Announces Upcoming Data Presentations at the American Society of Nephrology’s Virtual Kidney Week 2020

24/7 Wall Street - 1 month ago

With earnings season about to kick off, investors are being forced into a different sort of earnings season.

Other stocks mentioned: AMGN, GILD, NBIX
Zacks Investment Research - 1 month ago

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 1 month ago

Alexion (ALXN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Investment Research - 1 month ago

Alexion (ALXN) announces plans to increase its 2020 sales guidance by more than $200 million and buy back $3 billion of stock.

The Motley Fool - 1 month ago

Drug developers don't get much cheaper than this.

Other stocks mentioned: EXEL, JAZZ
Seeking Alpha - 1 month ago

Alexion Pharmaceuticals: More Potential Ahead Despite Upbeat Guidance

24/7 Wall Street - 1 month ago

Announcements that Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) made at its virtual Investor Day about expanding its pipeline and its guidance led to a handy gain in its shares on Tuesday.

Investors Business Daily - 1 month ago

Alexion Pharmaceuticals, citing a 'robust pipeline' across seven rare disease franchises, said ahead of its Virtual Investor Day that it expects to hike its sales guidance; ALXN stock rose. Th...

Market Watch - 1 month ago

Shares of Alexion Pharmaceuticals Inc. ALXN, +3.31% rose 1.5% in premarket trading Tuesday, after the biopharmaceutical company said it expects to raise its 2020 revenue guidance by more than ...

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Alexion Highlights Promising Pipeline & Distinguished Rare Disease Capabilities at Virtual Investor Day

The Motley Fool - 2 months ago

Their addressable markets may be small, but that doesn't mean developers will fail to profit from these boundary-breaking drugs.

Other stocks mentioned: VRTX

About ALXN

Alexion Pharmaceuticals develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia;... [Read more...]

Industry
Biotechnology
IPO Date
Feb 28, 1996
CEO
Leonard Bell
Employees
3,082
Stock Exchange
NASDAQ
Ticker Symbol
ALXN
Full Company Profile

Financial Performance

In 2019, ALXN's revenue was $4.99 billion, an increase of 20.81% compared to the previous year's $4.13 billion. Earnings were $2.40 billion, an increase of 2,998.32%.

Financial Statements

Analyst Forecasts

According to 25 analysts, the average rating for ALXN stock is "Buy." The 12-month stock price forecast is 145.35, which is an increase of 20.18% from the latest price.

Price Target
$145.35
(20.18% upside)
Analyst Consensus: Buy